Rabeprazole

Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).

Rabeprazole Gastro-Resistant Tablets (20mg) is a second-generation proton pump inhibitor on the WHO Model List of Essential Medicines. It binds to gastric H+/K+-ATPase with high potency and dissociates more rapidly than first-generation PPIs, producing faster acid inhibition within hours of the first dose. Indicated for acute duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.

Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).

Rabeprazole Sodium (20mg gastro-resistant) and Itopride Hydrochloride (150mg prolonged-release) combines an antisecretory PPI with an AChE-inhibiting and D2-antagonizing prokinetic. Itopride boosts acetylcholine availability to coordinate gastroduodenal contractions without prolonging cardiac QT intervals or elevating prolactin substantially. Indicated for GERD, reflux esophagitis, non-erosive reflux disease (NERD), and dysmotility-like functional dyspepsia.

Aceclofenac (200mg sustained-release) and Rabeprazole Sodium (20mg enteric-coated) Capsules is a gastro-protective NSAID combination. Aceclofenac is a phenylacetic acid NSAID that selectively inhibits COX-2 over COX-1, relieving joint pain and inflammation in osteoarthritis and ankylosing spondylitis. Rabeprazole is a fast-acting proton pump inhibitor that suppresses gastric acid secretion by blocking parietal cell H+/K+-ATPase, neutralizing the risk of NSAID-induced gastric ulceration, erosions, and GI bleeding. Indicated for chronic arthritis pain, osteoarthritis, and ankylosing spondylitis in patients with high gastrointestinal risk.

Rabeprazole Sodium (20mg) and Mosapride Citrate (15mg) combines a rapid gastric acid suppressor with a selective 5-HT4 agonist prokinetic. It suppresses acid secretion while promoting gastric emptying and duodenal coordination, reducing acid contact time on esophageal mucosa. Indicated for GERD, reflux esophagitis, and chronic dyspepsia with dysmotility symptoms.